Asherman's Syndrome, Cell Senescence, Thin Endometrial Lining
Conditions
Brief summary
The goal of this observational study is to determine if thin endometrial lining that is unresponsive to estrogen might be associated with the presence of senescent cells in patients following long-term use of oral contraceptives. The main question it aims to answer is: Are there any senescent cells present in thin endometrial lining? During the luteal phase of the cycle, participants will will undergo: * Gynecologic US to measure the endometrial lining thickness and pattern. * Endometrial biopsy with Pipelle catheter
Detailed description
The investigators hypothesized that senescent cells in the endometrium may be the cause of the failure of thin endometrium to respond to normal growth stimuli such as estrogen. The outcome that research team anticipate to measure is the percentage of senescent cells in the endometrial biopsies of women with thin endometrium compared to the control group biopsies.
Interventions
PROCEDUREEndometrial Biopsy
An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial biopsies are commonly done to check for the window of implantation, to determine ovulation or for enhancing implantation (procedure called endometrial scratching). For this purpose, we will use a Pipelle catheter. This procedure is very common in gynecologic practice and generally considered safe. In most of the cases this procedure is indicated for evaluation of irregular vaginal bleeding, vaginal bleeding in post-menopausal women and for infertility related problems (recurrent implantation failures for example).
Sponsors
Trio Fertility
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 39 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-39 * BMI - up to 35 * Thin endometrium after OCP use * Asherman's syndrome * Women already undergoing endometrial biopsy for infertility testing (eg. EMMA testing) * Women with archived endometrial biopsy samples
Exclusion criteria
* Women with systemic disease (Rheumatic disease, DM) * Women with coagulopathies * Women with active pelvic inflammatory process * Uterine anomalies * Pregnant women * Any hormonal contraception use or IUD
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Senescent cells presence | Through study completion, an average of 3 years. | Percentage of senescent cells in the endometrial biopsies of women with thin endometrium compared to the control group biopsies. |
Countries
Canada
Outcome results
None listed